selinexor + luspatercept

Selinexor + luspatercept is an investigational combination therapy consisting of two distinct agents with complementary mechanisms. Selinexor is a first-in-class selective inhibitor of nuclear export (SINE) that targets exportin 1 (XPO1), leading to the accumulation of tumor suppressor proteins in the nucleus and induction of apoptosis in malignant cells. Luspatercept is a recombinant fusion protein that acts as an erythroid maturation agent by binding select TGF-beta superfamily ligands to reduce Smad2/3 signaling and enhance late-stage erythropoiesis. The combination is being studied for its potential to address anemia and disease burden in patients with bone marrow fibrosis-associated anemia who are transfusion-dependent and refractory or intolerant to ruxolitinib[4]. Both drugs are approved individually for other hematologic indications but are under investigation together primarily for myelofibrosis-related anemia.